Pharmos preclinical data

PARS (New York) presented animal data showing that the derivative of tamoxifen was more active in mice bearing human breast tumors. Tumor size was decreased significantly in 90 percent of animals treated (n=10, p<0.001). In four animals, tumor was not measurable at six weeks, and only one did not respond.

The drug did not enter the brain, and had less estrogenic activity in the uterus than tamoxifen. However, it retained estrogenic effects in the bone, thus retaining the anti-osteoporosis effect of tamoxifen. Therefore, the company said at the meeting of the American Chemical Society in Anaheim, Calif., a better profile of side effects is expected from the drug compared to tamoxifen. ...